ChiCTR2500104879 版本V1.0 版本创建时间2025/06/25 09:36:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500104879 

最近更新日期:

Date of Last Refreshed on:

2025-06-25 09:36:01 

注册时间:

Date of Registration:

2025-06-25 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

瞳孔成形联合房角分离术治疗伴瞳孔散大闭角型青光眼的临床研究

Public title:

Clinical study on pupilloplasty combined with goniosynechialysis for angle-closure glaucoma with pupillary dilation.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

瞳孔成形联合房角分离术治疗伴瞳孔散大闭角型青光眼的临床研究

Scientific title:

Clinical study on pupilloplasty combined with goniosynechialysis for angle-closure glaucoma with pupillary dilation.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杜秀娟 

研究负责人:

杜秀娟 

Applicant:

Du Xiujuan 

Study leader:

Du Xiujuan 

申请注册联系人电话:

Applicant telephone:

+86 159 6662 4342

研究负责人电话:

Study leader's
telephone:

+86 159 6662 4342

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

duxiujuan2014@163.com

研究负责人电子邮件:

Study leader's E-mail:

duxiujuan2014@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

济南市英雄山路48号

研究负责人通讯地址:

济南市英雄山路48号

Applicant address:

48 Yingxiong Mountain Road, Ji'nan, Shandong, China

Study leader's address:

48 Yingxiong Mountain Road, Ji'nan, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东中医药大学附属眼科医院

Applicant's institution:

Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine

研究负责人所在单位:

山东中医药大学附属眼科医院

Affiliation of the Leader:

Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HEC-KS-2024048KY

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东中医药大学附属眼科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Affilated Eye Hospital of Shandong University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-26 00:00:00

伦理委员会联系人:

李晓鹏

Contact Name of the ethic committee:

Li Xiaopeng

伦理委员会联系地址:

济南市英雄山路48号

Contact Address of the ethic committee:

48 Yingxiong Mountain Road, Ji'nan, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 531 5885 9695

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东中医药大学附属眼科医院

Primary sponsor:

Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

济南市英雄山路48号

Primary sponsor's address:

48 Yingxiong Mountain Road, Ji'nan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学附属眼科医院

具体地址:

英雄山路48号

Institution
hospital:

Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine

Address:

48 Yingxiong Mountain Road

经费或物资来源:

瞳孔成形联合白内障房角分离术治疗大瞳孔闭角型青光眼的临床研究(编号:202307021577)

Source(s) of funding:

Clinical Study on Pupilloplasty Combined with Cataract Surgery and Goniosynechialysis in the Treatment of Angle-Closure Glaucoma with Pupillary Dilation (No. 202307021577)

研究疾病:

青光眼  

Target disease:

Glaucoma

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

(1). 评估瞳孔成形联合白内障超声乳化人工晶状体植入房角分离术治疗大瞳孔闭角型青光眼的可行性和安全性。 (2). 分析瞳孔成形联合白内障房角分离术降低眼压的效果,观察术后房角开放情况及其对青光眼病情的改善。 (3). 探讨瞳孔成型术与白内障房角分离术联合应用对术后视功能恢复和生活质量的影响。 (4). 比较瞳孔成型术联合白内障房角分离术与单纯白内障联合房角分离术在临床疗效上的差异,为临床治疗提供科学依据。  

Objectives of Study:

(1). Evaluate the feasibility and safety of pupil shaping combined with phacoemulsification and intraocular lens implantation for angle separation surgery in the treatment of large pupil angle closure glaucoma. (2). Analyze the effect of pupil shaping combined with cataract angle separation surgery on reducing intraocular pressure, observe the postoperative angle opening and its improvement on glaucoma condition. (3). Exploring the combined application of pupillary shaping surgery and cataract angle separation surgery on postoperative visual function recovery and quality of life. (4). Compare the clinical efficacy differences between pupillary shaping surgery combined with cataract angle separation surgery and simple cataract combined with angle separation surgery, and provide scientific basis for clinical treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

诊断为急性闭角型青光眼;瞳孔散大(瞳孔直径>5mm),直接对光反射和间接对光反射消失;术前畏光症状明显;合并白内障;白内障术后均植入同一种IOL;术前及术后检查评估资料齐全;术后能按时接受随访。

Inclusion criteria

Diagnosed as acute angle closure glaucoma; Pupil dilation (pupil diameter>5mm), disappearance of direct and indirect light reflexes; Preoperative photophobia symptoms are obvious; Combined cataract; After cataract surgery, the same type of IOL was implanted; Complete preoperative and postoperative examination and evaluation data; Can receive timely follow-up after surgery.

排除标准:

诊断为继发性青光眼;视力数指以下;合并角膜白斑、角膜溃疡变等角膜疾病;合并葡萄膜炎;合并视网膜脱离、眼底出血、糖尿病视网膜病变等其他严重影响视力的眼底疾病;患者拒绝或无法配合检查者。不能进行随访;

Exclusion criteria:

Diagnosed as secondary glaucoma; Visual acuity refers to the following; Combining corneal diseases such as leukoplakia and corneal ulceration; Combined uveitis; Other fundus diseases that seriously affect vision, such as retinal detachment, fundus hemorrhage, diabetes retinopathy, etc; The patient refuses or is unable to cooperate with the examiner. Cannot conduct follow-up;

研究实施时间:

Study execute time:

From 2024-12-26 00:00:00 To 2026-05-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-30 00:00:00 To 2025-12-25 00:00:00

干预措施:

Interventions:

组别:

观察组一

样本量:

18

Group:

Observation Group 1

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

观察组二

样本量:

18

Group:

Observation Group 2

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学附属眼科医院 

单位级别:

三甲 

Institution
hospital:

Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

最佳矫正视力

指标类型:

主要指标

Outcome:

Best-Corrected Visual Acuity (BCVA)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼压

指标类型:

主要指标

Outcome:

intraocular pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瞳孔直径

指标类型:

主要指标

Outcome:

Pupil diameter

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

角膜内皮计数

指标类型:

次要指标

Outcome:

Corneal Endothelial Cell Density

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

电脑视野

指标类型:

次要指标

Outcome:

automated perimetry

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视功能相关生存质量量表

指标类型:

次要指标

Outcome:

visualfunction questionnaire-25

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声生物显微镜

指标类型:

主要指标

Outcome:

Ultrasound Biomicroscopy,UBM

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

光学相干断层成像

指标类型:

次要指标

Outcome:

OCT

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人工晶体度数测量+眼轴+前房深度+角膜曲率

指标类型:

主要指标

Outcome:

IOL-Master

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

房角镜检查

指标类型:

主要指标

Outcome:

gonioscope examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

投稿时作为补充材料提交网站 http://www.medresman.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Submit your manuscript to the website as a supplementary material at the time of submission http://www.medresman.org.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

利用山东中医药大学附属眼科医院自建软件平台进行采集管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The software platform built by the Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine was used for collection and management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-06-25 09:36:01